Daxor (FRA:DX5) Research & Development: €0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DX5 Daxor Corp FRA:DX5
51 GF Score
Price €7.90
GF Value €29.07
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Daxor Research & Development?

Daxor FRA:DX5 -3.66% 51 Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:DX5 with a GF Score™ of 51/100 and a GF Value™ of €29.07 (Possible Value Trap). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Daxor's Research & Development for the six months ended in Dec. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Daxor  (FRA:DX5) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Daxor Research & Development Related Terms

Daxor Research & Development Historical Data

* Premium members only.

The historical data trend for Daxor's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daxor Research & Development Chart

Daxor Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Daxor Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:DX5
51GF Score
Daxor Corp FRA:DX5
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Daxor Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Daxor (FRA:DX5) has a Research & Development of €0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Daxor and its competitors.
Is Daxor's Research & Development too high?
Daxor's current Research & Development is €0.00 Mil. Overall, Daxor has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Daxor's Research & Development compare to POCI and NEPH?
Daxor's Research & Development of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Daxor and its competitors. Daxor's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daxor stock overvalued right now?
Based on GuruFocus' analysis, Daxor (FRA:DX5) is currently considered Possible Value Trap. The stock's GF Value™ is €29.07, compared to a current price of €7.90 — trading 72.8% below its estimated fair value. The current Research & Development is €0.00 Mil. Daxor's overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Daxor (FRA:DX5), the current Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Daxor (FRA:DX5) Overvalued in 2026?

Based on GuruFocus' analysis, Daxor stock appears to be undervalued. The current stock price of €7.90 is trading 72.8% below its estimated GF Value™ of €29.07. GuruFocus considers Daxor to be Possible Value Trap.

Key valuation signals for FRA:DX5:

  • Research & Development: €0.00 Mil
  • GF Value™: €29.07 vs. price of €7.90 (72.8% below fair value)
  • GF Score™: 51/100 with 1 warning sign

No single metric tells the full story. See the FRA:DX5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Daxor Business Description

Other Exchanges DXR:USA
Address 107 Meco Lane, Oak Ridge, TN, USA, 37830
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
51GF Score

Get the complete analysis for FRA:DX5

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.90
Price
€29.07
GF Value